Description: Microbix Biosystems Inc. is a life science company and manufacturer of viral and bacterial antigens and reagents for the diagnostics industry. The Company develops biological products and technologies. The Company operates in two segments: the development, manufacturing and distribution of cell-based products and technology, and the provision of facility, technical and production personnel for contract research and development. The Company's Virology Products (Virology) business manufactures and sells cell culture-based biological products. The Company's pipeline of technologies and products include Kinlytic, which is a thrombolytic drug with various applications, including the treatment of life-threatening blood clots, and LumiSort, which is a semen sexing technology for the livestock industries. It operates in three geographical areas, including North America, Europe and in other foreign countries. It owns and operates a Virology manufacturing facility at Mississauga, Ontario.
Home Page: microbix.com
MBX Technical Analysis
265 Watline Avenue
Mississauga,
ON
L4Z 1P3
Canada
Phone:
905 361 8910
Officers
| Name | Title |
|---|---|
| Mr. Cameron L. Groome | Pres, CEO & Director |
| Mr. James S. Currie | Chief Financial Officer |
| Dr. Kenneth Hughes Ph.D. | Chief Operating Officer |
| Dr. Mark Luscher Ph.D. | Sr. VP of Scientific Affairs |
| Mr. Philip Casselli | Sr. VP of Sales, Bus. Devel. & Marketing |
| Mr. Christopher B. Lobb | Compliance Officer, Gen. Counsel & Sec. |
Exchange: TO
Country: CA : Canada
Currency: Canadian Dollar (C$)
| Forward PE: | 9.5511 |
|---|---|
| Trailing PE: | 39 |
| Price-to-Book MRQ: | 2.4715 |
| Price-to-Sales TTM: | 2.8648 |
| IPO Date: | |
| Fiscal Year End: | September |
| Full Time Employees: | 0 |